Similar results are seen for other mutation-targeted agents including epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (NSCLC) [25–28], BRAF inhibitors in melanoma [29, 30], and HER2 inhibition in breast cancer [31, 32]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.